tm
Seeing Is Believing
tm
Seeing Is Believing
PRLD is currently covered by 2 analysts with an average price target of $3.01. This is a potential upside of $0.99 (49.01%) from yesterday's end of day stock price of $2.02.
Prelude Therapeutics 's activity chart (see below) currently has 47 price targets and 39 ratings on display. The stock rating distribution of PRLD is 100% BUY.
Analysts average stock forecasts to be materialized ratio is 36.86% with an average time for these price targets to be met of 74.2 days.
Highest price target for PRLD is $5, Lowest price target is $3, average price target is $4.
Most recent stock forecast was given by ROBERT BURNS from HC WAINWRIGHT on 23-Sep-2025. First documented stock forecast 20-Oct-2020.
Currently out of the existing stock ratings of PRLD, 6 are a BUY (100%).
Analyst name
Rating
Rating initiation date
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
Since 19-Sep-2024
$5
$2.98 (147.52%)
4 months 1 days ago
(23-Sep-2025)
5/14 (35.71%)
$3.97 (385.44%)
100
Buy
Since 13-Mar-2024
$3
$0.98 (48.51%)
$4
5 months 6 days ago
(18-Aug-2025)
1/5 (20%)
$2.06 (219.15%)
77
Sell
Since 28-Oct-2024
$1
$-1.02 (-50.50%)
$5
1 years 2 months 27 days ago
(28-Oct-2024)
2/5 (40%)
$-0.5 (-33.33%)
136
Sell
Since 19-Dec-2023
$4
$1.98 (98.02%)
$10
2 years 1 months 5 days ago
(19-Dec-2023)
2/7 (28.57%)
$-0.04 (-0.99%)
4
Hold
Since 21-Nov-2022
$6
$3.98 (197.03%)
$10
3 years 2 months 3 days ago
(21-Nov-2022)
3/5 (60%)
$-0.53 (-8.12%)
54
What is PRLD (Prelude Therapeutics ) average time for price targets to be met?
Which analyst has the current highest performing score on PRLD (Prelude Therapeutics ) with a proven track record?
Which analyst has the current lower performing score on PRLD (Prelude Therapeutics ) with a proven track record?
Which analyst has the most public recommendations on PRLD (Prelude Therapeutics )?
Which analyst is the currently most bullish on PRLD (Prelude Therapeutics )?
Which analyst is the currently most reserved on PRLD (Prelude Therapeutics )?
